MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Epirus Biopharmaceuticals Company Profile (NASDAQ:EPRS)

Consensus Ratings for Epirus Biopharmaceuticals (NASDAQ:EPRS) (?)
Ratings Breakdown: 3 Hold Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $7.33 (1,186.55% upside)

Analysts' Ratings History for Epirus Biopharmaceuticals (NASDAQ:EPRS)
Show:
DateFirmActionRatingPrice TargetActions
5/15/2016Leerink SwannDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/11/2016BTIG ResearchDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/11/2016WedbushDowngradeOutperform -> Neutral$11.00 -> $2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/26/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha